Oruka Therapeutics, Inc. - 8-K Filing
Oruka Therapeutics expanded its IL-23 license agreement with Paragon Therapeutics on May 29, 2026 to include inflammatory bowel disease (IBD) in the 'Field' definition. The amendment allows Oruka to pursue IBD indications but restricts human dosing of ORKA-001 for combination therapy until June 1, 2028 and monotherapy until June 1, 2030. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ORKA